Grandfield & Dodd LLC Sells 249 Shares of Eli Lilly and Company $LLY

Grandfield & Dodd LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 9.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,279 shares of the company’s stock after selling 249 shares during the quarter. Grandfield & Dodd LLC’s holdings in Eli Lilly and Company were worth $1,777,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LLY. Brighton Jones LLC raised its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd lifted its holdings in Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after purchasing an additional 85 shares in the last quarter. Kaufman Rossin Wealth LLC bought a new position in Eli Lilly and Company in the 1st quarter worth about $242,000. Finally, Opes Wealth Management LLC grew its holdings in Eli Lilly and Company by 6.6% during the 1st quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock valued at $278,000 after buying an additional 21 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.4%

Shares of LLY stock opened at $1,022.00 on Friday. The business has a 50-day moving average price of $820.93 and a two-hundred day moving average price of $779.85. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,032.95. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The firm has a market cap of $966.19 billion, a P/E ratio of 66.80, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period last year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Analyst Upgrades and Downgrades

Several research analysts have commented on LLY shares. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Guggenheim restated a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $999.32.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.